A Covid-19 vaccine could be broadly rolled out in the United States by the middle of 2021 or a little later, the head of the federal government’s disease control agency said.

The U.S. Food and Drug Administration said AstraZeneca Plc’s Covid-19 vaccine trial in the United States is still on hold, and the FDA was working with the company to figure out if there was a significant safety issue or not.

Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.

Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.

Becton Dickinson is investigating reports from U.S. nursing homes that the company’s rapid coronavirus testing equipment is producing false-positive results.

Seven U.S. states reported record one-day increases in Covid-19 cases so far in September even as the average daily number of new infections is falling nationally.

The number of new cases of the novel coronavirus reported in the United States fell 15 percent last week from the previous seven days, and deaths fell for a fourth week in a row, according to a Reuters analysis.

AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

AstraZeneca resumed British clinical trials of the company’s Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

Political polarization and online misinformation are threatening vaccination programs worldwide, with public trust volatile and varying widely between countries, according to a global vaccine confidence study.